Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype

被引：0
|
作者：
Marotta, G [1 ]
Bigazzi, C [1 ]
Bocchia, M [1 ]
Forconi, F [1 ]
Lauria, F [1 ]
机构：
[1] Univ Siena, A Sclavo Hosp, Div Hematol, I-53100 Siena, Italy
来源：
HAEMATOLOGICA | 1998年 / 83卷 / 09期
关键词：
non Hodgkin lymphoma; ProMACE-CytaBOM regimen; long-term follow-up;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were evaluated. Twenty-four out of 54 (45%) patients achieved a complete remission and 13 of them are still in continuous remission with a median survival of 53.5 months. Interestingly, in 16 patients with intermediate grade histology we obtained an overall response rate of 100%.
引用
收藏
页码：853 / 854
页数：2
相关论文
共 50 条
  • [41] A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant
    Laporte, JP
    Yeshurun, M
    Fouillard, L
    Labopin, M
    Cailliot, C
    Lesage, S
    Isnard, F
    Najman, A
    Gorin, NC
    LEUKEMIA, 2004, 18 (10) : 1717 - 1721
  • [42] Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma
    Kong, LR
    Huang, CF
    Hakimian, D
    Variakojis, D
    Klein, L
    Kuzel, TM
    Gordon, LI
    Zanzig, C
    Wollins, E
    Tallman, MS
    CANCER, 1998, 82 (05) : 957 - 964
  • [43] Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma
    Beksaç, M
    Idilman, R
    CANCER, 1999, 85 (01) : 242 - 243
  • [44] Long-term follow-up in aggressive non-Hodgkin's lymphoma (NHL) patients treated with rHuG-CSF(lenograstim) combined biweekly CHOP chemotherapy.
    Dan, K
    Ogura, M
    Oyama, A
    Asano, S
    BLOOD, 2001, 98 (11) : 344A - 344A
  • [45] What is the Price of survival in Hodgkin's lymphoma?: Long-term follow-up of cured patients
    Zsofia, Miltenyi
    Katalin, Keresztes
    Judit, Vegh
    Gyorgy, Szekely
    Arpad, Illes
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) : 178 - 183
  • [46] Long-term results with rituximab in previously-treated patients with low-grade non-Hodgkin's lymphoma.
    Case, DC
    Boyd, MA
    Hedlund, JA
    Ebrahim, KA
    Aronson, FR
    BLOOD, 2003, 102 (11) : 294B - 294B
  • [47] Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma.: Final report of a multicenter trial conducted by GISL
    Federico, M
    Clò, V
    Burgiatelli, M
    Carotenuto, M
    Gobbi, PG
    Vallisa, D
    Lombardo, M
    Avanzini, P
    Di Renzo, N
    Dini, D
    Baldini, L
    Silingardi, V
    HAEMATOLOGICA, 1998, 83 (09) : 800 - 811
  • [48] A phase I study of dose-intensified promace-cytabom with prophylactic granulocyte colony stimulating factor (G-CSF) for patients (PTS) with non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    Camoriano, JK
    Schroeder, G
    Kurtin, PJ
    Habermann, TM
    BLOOD, 1996, 88 (10) : 2263 - 2263
  • [49] Long-term follow up of patients with relapsed non-Hodgkin lymphoma receiving autologous stem cell transplantation
    Link, C.
    Scheele, J.
    Kramer, M.
    Schetelig, J.
    Haenel, M.
    Bornhaeuser, M.
    Ehninger, G.
    Kroschinsky, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 145 - 145
  • [50] Long-term follow up of patients with relapsed non-Hodgkin lymphoma receiving allogeneic stem cell transplantation
    Link, C.
    Mies, F.
    Kramer, M.
    Schetelig, J.
    Haenel, M.
    Bornhaeser, M.
    Ehninger, G.
    Kroschinsky, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 132 - 132
12345